4D Molecular Therapeutics, Inc. (FDMT) dividends
FDMT on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
4D Molecular Therapeutics, Inc. dividend: key facts
Own 4D Molecular Therapeutics, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next FDMT dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Results, reports and dividend announcements
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- 4DMT Announces New Employment Inducement Grants13 Nov 2026 · GlobeNewsWire
EMERYVILLE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
- 4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones13 Nov 2026 · GlobeNewsWire
Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 ...
- 4DMT to Participate in Upcoming Investor Conferences3 Nov 2026 · GlobeNewsWire
EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t...
- 4DMT to Host Investor Day on October 21, 202610 Oct 2026 · GlobeNewsWire
Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C.
- Ocular Therapeutix shares down 22% after 4D Molecular announces Phase 3 results3 Oct 2026 · TheFly
Shares of Ocular Therapeutix (OCUL) are down 22% to $7.53 in morning trading after competitor 4D Molecular Therapeutics (FDMT) announced Phase 3 clinical data for its wet age-related macular degenerat...
- 4D Molecular price target raised to $33 from $29 at BofA3 Oct 2026 · TheFly
BofA raised the firmâs price target on 4D Molecular (FDMT) to $33 from $29 and keeps a Buy rating on the shares after the company reported two-year data from theâ¦
- 4D Molecular announces first patients enrolled in 4SIGHT Phase 3 trial3 Oct 2026 · TheFly
4D Molecular (FDMT) Therapeutics announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular...
- 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME3 Oct 2026 · GlobeNewsWire
EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted ...
Insufficient verified data for a financial-health score
Dividend data and price last updated 17 Nov 2026.